[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100285296":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":13,"locations":22,"responsibleParty":38,"collaborators":41,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":7,"eligibilityCriteria":58,"healthyVolunteers":54,"sex":59,"minAge":7,"maxAge":7,"enrollmentInfo":60,"targetDuration":63,"studyType":64,"phases":7,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":24,"whyStopped":7,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"State University of New York at Buffalo","OTHER",null,[9],{"name":10,"affiliation":11,"role":12},"Thomas J. Langan, MD","Clinical Director, Clinical Research, Institute for Myelin and Glial Exploration","PRINCIPAL_INVESTIGATOR",[14,18],{"name":10,"role":15,"phone":16,"phoneExt":7,"email":17},"CONTACT","716-888-4732","tjlangan@buffalo.edu",{"name":19,"role":15,"phone":20,"phoneExt":7,"email":21},"Amy Barczykowski","716-829-6101","alp38@buffalo.edu",[23],{"facility":5,"status":24,"city":25,"state":26,"zip":27,"country":28,"countryCode":29,"cosmosGeoPoint":30,"geoPoint":35,"contacts":36},"RECRUITING","Buffalo","New York","14203","United States","US",{"type":31,"coordinates":32},"Point",[33,34],-78.87837,42.88645,{"lat":34,"lon":33},[37],{"name":10,"role":15,"phone":16,"phoneExt":7,"email":17},{"type":12,"investigatorFullName":39,"investigatorTitle":40,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"Thomas J. Langan","Principal Investigator",[42,45,48,50],{"name":43,"class":44},"Rare Diseases Clinical Research Network","NETWORK",{"name":46,"class":47},"National Center for Advancing Translational Sciences (NCATS)","NIH",{"name":49,"class":6},"Lysosomal Disease Network",{"name":51,"class":47},"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","100285296","krabbe-disease-global-patient-registry-100285296",false,"NCT02993796","Krabbe Disease Global Patient Registry","The Institute for Myelin and Glia Exploration's Clinical Database of Patients With Krabbe Disease, A World-Wide Registry","Inclusion Criteria:\n\n* Anyone diagnosed with Krabbe disease\n* Anyone at-risk for Krabbe disease\n* Family members of someone diagnosed with, or at-risk for, Krabbe disease.\n\nExclusion Criteria:\n\n* Anyone who is not diagnosed with, or at-risk for, Krabbe disease\n* Anyone who is not a family member of someone diagnosed with, or at-risk for, Krabbe disease","ALL",{"count":61,"type":62},60,"ESTIMATED","5 Years","OBSERVATIONAL","The purpose of this study is to develop a clinical database of individuals diagnosed with Krabbe disease in order to determine which symptoms herald the onset of clinical disease in the various phenotypes of Krabbe disease; to determine whether level of GALC enzyme activity, or a specific genetic mutation predict the clinical course; and to determine which neurodiagnostic tests predict onset and\u002For severity of the disease.",[67],"Krabbe Disease",[69,70,71,72],"Krabbe disease","globoid cell leukodystrophy","galactosylceramide lipidosis","sphingolipidosis","2025-02-07",{"date":75,"type":76},"2025-02-10","ACTUAL",{"date":78,"type":76},"2014-09",{"date":80,"type":62},"2026-09",{"name":5,"class":6},1]